Literature DB >> 7056278

Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

R Larsson, P Erlanson, G Bodemar, B Norlander, L Fransson, L Strouth.   

Abstract

A single intravenous dose of cimetidine 200mg was administered to 6 patients with severe chronic renal failure one hour prior to haemodialysis. The plasma concentrations of cimetidine and its sulphoxide metabolite at the start of haemodialysis were 2.74 +/- 0.12 and 0.76 +/- 0.08 microgram/ml, and after dialysis for 4h 1.08 +/- 0.10 and 0.51 +/- 0.08 microgram/ml, respectively (mean +/- SE). The average haemodialysis clearance (ClHDa) of cimetidine during dialysis was 46-92 ml/min at a dialysate flow rate of 320 ml/min and blood flow rates in the 6 patients between 160-240 ml/min. The mean ClHDa of the sulphoxide metabolite was 44% higher than that of cimetidine, and ranged between 49-148 ml/min. During haemodialysis the mean plasma elimination half-life (t 1/2) of cimetidine was 3.24h (range 2.08-5.08) and of the sulphoxide metabolite 9.49h (range 4.70-14.39). There was a significant relationship between the elimination rate constant (beta) and ClHDa of the sulphoxide metabolite (p less than 0.01), but no such relationship was found between beta and ClHDa of cimetidine. The mean total amount of cimetidine eliminated during dialysis was 27.3mg (range 17.9-31.8), which was 9.0-15.9% of the given dose. Between 12.2-21.2mg (mean 15.3) of the sulphoxide metabolite was eliminated in the dialysate. Major adjustment of the dose of cimetidine on days of dialysis is not necessary.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7056278     DOI: 10.1007/bf00637621

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  28 in total

1.  A rapid and precise method for the determination of urea.

Authors:  J K FAWCETT; J E SCOTT
Journal:  J Clin Pathol       Date:  1960-03       Impact factor: 3.411

2.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

3.  Oral absorption of cimetidine and its clearance in patients with renal failure.

Authors:  R Larsson; G Bodemar; B Norlander
Journal:  Eur J Clin Pharmacol       Date:  1979-04-17       Impact factor: 2.953

4.  Therapeutic effect of cimetidine in patients undergoing haemodialysis.

Authors:  R H Jones; M R Lewin; V Parsons
Journal:  Br Med J       Date:  1979-03-10

5.  Cimetidine and renal failure.

Authors:  W Grave; J N Nadorp; J J Rutten
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

6.  High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine.

Authors:  R M Lee; P M Osborne
Journal:  J Chromatogr       Date:  1978-09-01

7.  Cimetidine potentiation of the hypoprothrombinemic effect of warfarin.

Authors:  B A Silver; W R Bell
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

8.  Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients.

Authors:  A Somogyi; H G Rohner; R Gugler
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

9.  Effects of renal failure on blood levels of cimetidine.

Authors:  K W Ma; D C Brown; D S Masler; S E Silvis
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

10.  Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol.

Authors:  C S Lee; T C Marbury; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1980-02
View more
  10 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

3.  Human jejunal permeability of two polar drugs: cimetidine and ranitidine.

Authors:  N Takamatsu; O N Kim; L S Welage; N M Idkaidek; Y Hayashi; J Barnett; R Yamamoto; E Lipka; H Lennernäs; A Hussain; L Lesko; G L Amidon
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Effect of omeprazole and cimetidine on plasma diazepam levels.

Authors:  T Andersson; K Andrén; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Removal of famotidine by haemodialysis in elderly anuric patients.

Authors:  N Inotsume; M Nishimura; M Nakano; S Fujiyama; K Sagara; T Sato; K Matsushita; Y Imai; H Matsui
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.

Authors:  E Lunell; O Borgå; R Larsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

9.  Cimetidine, but not oxmetidine, penetrates into the cerebrospinal fluid after a single intravenous dose.

Authors:  K A Jönsson; S E Eriksson; I Kagevi; B Norlander; G Bodemar; A Walan
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

Review 10.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.